Background: Glutamate deregulation may be involved in the neuropathology of schizophrenia, mainly through N-methyl-D-aspartate receptor (NMDAR) dysfunction. Memantine, which is approved for Alzheimer's disease, acts as a nonselective NMDAR antagonist. There have been some mixed results in some preliminary studies about adding memantine to antipsychotics in patients with schizophrenia in terms o...

PURPOSE It is well known that acute exposure to high concentrations of glutamate is toxic to central mammalian neurons. However, the effect of a chronic, minor elevation over endogenous glutamate levels has not been explored. The authors have suggested that such chronic exposure may play a role in glaucomatous neuronal loss. In the current study, they sought to explore whether a chronic, low-do...

AIM Following severe peripheral nerve injury (PNI), regeneration is often insufficient and functional recovery is incomplete. In this regard, glutamate N-methyl-D-aspartate (NMDA) receptor antagonist such as Memantine have been shown to have neuroprotective effects. We evaluated the effects of Memantine against sciatic nerve crush injury in male Wistar Rats. MATERIAL AND METHODS Memantine or ...

Memantine is a N-methyl-D-aspartate (NMDA) receptor antagonist approved for the treatment of moderate to severe Alzheimer's disease (AD). Environmental enrichment (EE) has shown significant beneficial effects on functional improvement in AD. In this study, we sought to determine whether combining these two distinct therapies would yield greater benefit than either drug used alone. We investigat...

it has been hypothesized that elevated plasma homocysteine (hcy) plays a role in the pathogenesis of alzheimer’s disease (ad) and age-related cognitive decline. the mechanism of hcy neurotoxicity in the brain is controversial as well hcy is a ligand of nmda receptor. memantine, an uncompetitive antagonist of n-methyl-d-aspartate (nmda) receptors approved for the treatment of moderate to severe ...

Cholinergic and glutamatergic systems, alpha-7 nicotinic acetylcholine receptor (α-7nAChR) and N-methyl-D-aspartate (NMDA) receptor are strongly implicated with cognitive impairments in Alzheimer's disease (AD). Donepezil, a frequently used drug in the treatment of AD, is only an acetylcholinesterase inhibitor (AChEI), whereas galantamine is an AChEI and a positive allosteric modulator of the α...

BACKGROUND Findings from observational studies have suggested a delay in nursing home placement with dementia drug treatment, but findings from a previous randomised trial of patients with mild-to-moderate Alzheimer's disease showed no effect. We investigated the effects of continuation or discontinuation of donepezil and starting of memantine on subsequent nursing home placement in patients wi...

The objective of this study was to determine the effect of memantine on schizophrenia-like symptoms in a ketamine-induced social withdrawal model in rats. We examined therapeutic effects of memantine, an NMDA antagonist, and haloperidol, a classic antipsychotic drug, on this behavioral model. Administration of memantine (10 or 15 mg·kg(-1)) significantly reduced ketamine-induced social withdraw...

Memantine is a low-affinity, voltage-dependent, non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. It is classified as a neuroprotective aminoadamantane. It does not cure or reverse Alzheimer's but it does effectively treat symptoms, slows the progression of the disease and allows many patients to perform daily cognitive activities with clear thoughts. Based on it's success in pat...

Short-term tinnitus develops shortly after the administration of a high dose of salicylate. Since salicylate selectively potentiates N-methyl- D-aspartate (NMDA) currents in spiral ganglion neurons, it may play a vital role in tinnitus by amplifying NMDA-mediated neurotransmission. The aim of this study was to determine whether systemic treatment with a NMDA channel blocker, memantine, could pr...